OpenAccessBelV2, Main, Exploration, bibRecord, 001578

An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer

Identifieur interne : 001578 ( Main/Exploration ); précédent : 001577; suivant : 001579

An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer

Auteurs : M. Venturini [Italie] ; R. Paridaens [Belgique] ; D. Rossner [Allemagne] ; M. M. Vaslamatzis [Grèce] ; J. W. R. Nortier [Pays-Bas] ; M. Salzberg [Suisse] ; H. Rodrigues [Portugal] ; R. Bell [Australie]

Source :

Oncology [ 0030-2414 ] ; 2007.

RBID : Pascal:08-0002287

Descripteurs français

Pascal (Inist)
- Capécitabine, Etude multicentrique, Ambulatoire, Métastase, Homme, Stade avancé, Accessibilité, Programme, Traitement, Cancérologie, Anticancéreux, Monothérapie, Cancer du sein.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Accessibility, Advanced stage, Ambulatory, Antineoplastic agent, Breast cancer, Cancerology, Capecitabine, Human, Metastasis, Monotherapy, Multicenter study, Program, Treatment.

Abstract

Background: Phase Il/III trials have shown that capecitabine is an active, well-tolerated therapy for metastatic breast cancer (MBC). We report clinical findings from an expanded access program enabling patients ineligible for investigative trials to receive capecitabine before its approval and availability. Methods: Patients pretreated with at least two chemotherapy regimens, including a taxane, for MBC received oral capecitabine until disease progression or unacceptable toxicity. Results: Six hundred and thirty-one patients received capecitabine (mean duration 3.8 months, range 0.1-24.7 months). The most common treatment-related grade 3/4 toxicities were diarrhea (9%) and hand-foot syndrome (8%). Grade 3/4 alopecia was absent and grade 3/4 myelosuppression was rare. Dose was modified in 172 patients (27%). Objective response rate in 349 evaluable patients was 35%. Median time to progression (n = 604) was 6.6 months (95% confidence interval, Cl, 5.6-7.6) and median overall survival (n = 569) was 10.0 months (95% Cl, 8.5-15.3). Conclusions: Our findings in a cohort of patients with pretreated progressive breast cancer confirm the high efficacy and tolerability of outpatient capecitabine.

Affiliations:

Allemagne, Australie, Belgique, Grèce, Italie, Pays-Bas, Portugal, Suisse
Basse-Saxe, Hollande-Méridionale
Hanovre, Leyde

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000092
to stream PascalFrancis, to step Curation: 000057
to stream PascalFrancis, to step Checkpoint: 000079
to stream Main, to step Merge: 001585
to stream Main, to step Curation: 001578

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer</title>
<author><name sortKey="Venturini, M" sort="Venturini, M" uniqKey="Venturini M" first="M." last="Venturini">M. Venturini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Medical Oncology Department</s1>
<s2>Negrar</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Medical Oncology Department</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Paridaens, R" sort="Paridaens, R" uniqKey="Paridaens R" first="R." last="Paridaens">R. Paridaens</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University Hospital Gasthuisberg, Katholieke Universiteit Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rossner, D" sort="Rossner, D" uniqKey="Rossner D" first="D." last="Rossner">D. Rossner</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Medical University of Hannover</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vaslamatzis, M M" sort="Vaslamatzis, M M" uniqKey="Vaslamatzis M" first="M. M." last="Vaslamatzis">M. M. Vaslamatzis</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Medical Oncology, Evangelismos Hospital</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<wicri:noRegion>Athens</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nortier, J W R" sort="Nortier, J W R" uniqKey="Nortier J" first="J. W. R." last="Nortier">J. W. R. Nortier</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Salzberg, M" sort="Salzberg, M" uniqKey="Salzberg M" first="M." last="Salzberg">M. Salzberg</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University Hospital</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rodrigues, H" sort="Rodrigues, H" uniqKey="Rodrigues H" first="H." last="Rodrigues">H. Rodrigues</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Institute Portugues de Oncologia</s1>
<s2>Porto</s2>
<s3>PRT</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
<wicri:noRegion>Institute Portugues de Oncologia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bell, R" sort="Bell, R" uniqKey="Bell R" first="R." last="Bell">R. Bell</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Andrew Love Cancer Center, Geelong Hospital</s1>
<s2>Geelong</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Geelong</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0002287</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 08-0002287 INIST</idno>
<idno type="RBID">Pascal:08-0002287</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000092</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000057</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000079</idno>
<idno type="wicri:doubleKey">0030-2414:2007:Venturini M:an:open:label</idno>
<idno type="wicri:Area/Main/Merge">001585</idno>
<idno type="wicri:Area/Main/Curation">001578</idno>
<idno type="wicri:Area/Main/Exploration">001578</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer</title>
<author><name sortKey="Venturini, M" sort="Venturini, M" uniqKey="Venturini M" first="M." last="Venturini">M. Venturini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Medical Oncology Department</s1>
<s2>Negrar</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Medical Oncology Department</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Paridaens, R" sort="Paridaens, R" uniqKey="Paridaens R" first="R." last="Paridaens">R. Paridaens</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University Hospital Gasthuisberg, Katholieke Universiteit Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rossner, D" sort="Rossner, D" uniqKey="Rossner D" first="D." last="Rossner">D. Rossner</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Medical University of Hannover</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vaslamatzis, M M" sort="Vaslamatzis, M M" uniqKey="Vaslamatzis M" first="M. M." last="Vaslamatzis">M. M. Vaslamatzis</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Medical Oncology, Evangelismos Hospital</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<wicri:noRegion>Athens</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nortier, J W R" sort="Nortier, J W R" uniqKey="Nortier J" first="J. W. R." last="Nortier">J. W. R. Nortier</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Salzberg, M" sort="Salzberg, M" uniqKey="Salzberg M" first="M." last="Salzberg">M. Salzberg</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University Hospital</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rodrigues, H" sort="Rodrigues, H" uniqKey="Rodrigues H" first="H." last="Rodrigues">H. Rodrigues</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Institute Portugues de Oncologia</s1>
<s2>Porto</s2>
<s3>PRT</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
<wicri:noRegion>Institute Portugues de Oncologia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bell, R" sort="Bell, R" uniqKey="Bell R" first="R." last="Bell">R. Bell</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Andrew Love Cancer Center, Geelong Hospital</s1>
<s2>Geelong</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Geelong</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Oncology</title>
<title level="j" type="abbreviated">Oncology</title>
<idno type="ISSN">0030-2414</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Oncology</title>
<title level="j" type="abbreviated">Oncology</title>
<idno type="ISSN">0030-2414</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accessibility</term>
<term>Advanced stage</term>
<term>Ambulatory</term>
<term>Antineoplastic agent</term>
<term>Breast cancer</term>
<term>Cancerology</term>
<term>Capecitabine</term>
<term>Human</term>
<term>Metastasis</term>
<term>Monotherapy</term>
<term>Multicenter study</term>
<term>Program</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Capécitabine</term>
<term>Etude multicentrique</term>
<term>Ambulatoire</term>
<term>Métastase</term>
<term>Homme</term>
<term>Stade avancé</term>
<term>Accessibilité</term>
<term>Programme</term>
<term>Traitement</term>
<term>Cancérologie</term>
<term>Anticancéreux</term>
<term>Monothérapie</term>
<term>Cancer du sein</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Phase Il/III trials have shown that capecitabine is an active, well-tolerated therapy for metastatic breast cancer (MBC). We report clinical findings from an expanded access program enabling patients ineligible for investigative trials to receive capecitabine before its approval and availability. Methods: Patients pretreated with at least two chemotherapy regimens, including a taxane, for MBC received oral capecitabine until disease progression or unacceptable toxicity. Results: Six hundred and thirty-one patients received capecitabine (mean duration 3.8 months, range 0.1-24.7 months). The most common treatment-related grade 3/4 toxicities were diarrhea (9%) and hand-foot syndrome (8%). Grade 3/4 alopecia was absent and grade 3/4 myelosuppression was rare. Dose was modified in 172 patients (27%). Objective response rate in 349 evaluable patients was 35%. Median time to progression (n = 604) was 6.6 months (95% confidence interval, Cl, 5.6-7.6) and median overall survival (n = 569) was 10.0 months (95% Cl, 8.5-15.3). Conclusions: Our findings in a cohort of patients with pretreated progressive breast cancer confirm the high efficacy and tolerability of outpatient capecitabine.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Belgique</li>
<li>Grèce</li>
<li>Italie</li>
<li>Pays-Bas</li>
<li>Portugal</li>
<li>Suisse</li>
</country>
<region><li>Basse-Saxe</li>
<li>Hollande-Méridionale</li>
</region>
<settlement><li>Hanovre</li>
<li>Leyde</li>
</settlement>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Venturini, M" sort="Venturini, M" uniqKey="Venturini M" first="M." last="Venturini">M. Venturini</name>
</noRegion>
</country>
<country name="Belgique"><noRegion><name sortKey="Paridaens, R" sort="Paridaens, R" uniqKey="Paridaens R" first="R." last="Paridaens">R. Paridaens</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Basse-Saxe"><name sortKey="Rossner, D" sort="Rossner, D" uniqKey="Rossner D" first="D." last="Rossner">D. Rossner</name>
</region>
</country>
<country name="Grèce"><noRegion><name sortKey="Vaslamatzis, M M" sort="Vaslamatzis, M M" uniqKey="Vaslamatzis M" first="M. M." last="Vaslamatzis">M. M. Vaslamatzis</name>
</noRegion>
</country>
<country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Nortier, J W R" sort="Nortier, J W R" uniqKey="Nortier J" first="J. W. R." last="Nortier">J. W. R. Nortier</name>
</region>
</country>
<country name="Suisse"><noRegion><name sortKey="Salzberg, M" sort="Salzberg, M" uniqKey="Salzberg M" first="M." last="Salzberg">M. Salzberg</name>
</noRegion>
</country>
<country name="Portugal"><noRegion><name sortKey="Rodrigues, H" sort="Rodrigues, H" uniqKey="Rodrigues H" first="H." last="Rodrigues">H. Rodrigues</name>
</noRegion>
</country>
<country name="Australie"><noRegion><name sortKey="Bell, R" sort="Bell, R" uniqKey="Bell R" first="R." last="Bell">R. Bell</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001578 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001578 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Belgique
   |area=    OpenAccessBelV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:08-0002287
   |texte=   An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer
}}

This area was generated with Dilib version V0.6.25.
Data generation: Thu Dec 1 00:43:49 2016. Site generation: Wed Mar 6 14:51:30 2024

	Serveur d'exploration autour du libre accès en Belgique
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration autour du libre accès en Belgique

An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer

An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri